108 related articles for article (PubMed ID: 8846667)
1. Pharmacokinetics and dosimetry of [111In] F(ab')2 fragments against prostatic acid phosphatase after intraprostatic injection for immunoscintigraphy in prostate cancer.
Nielsen JT; Poulsen J; Flø C; Marqversen J; Rehling M
Clin Physiol; 1995 Sep; 15(5):467-81. PubMed ID: 8846667
[TBL] [Abstract][Full Text] [Related]
2. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
Virgolini I; Szilvasi I; Kurtaran A; Angelberger P; Raderer M; Havlik E; Vorbeck F; Bischof C; Leimer M; Dorner G; Kletter K; Niederle B; Scheithauer W; Smith-Jones P
J Nucl Med; 1998 Nov; 39(11):1928-36. PubMed ID: 9829585
[TBL] [Abstract][Full Text] [Related]
3. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
Peräalä-Heape M; Vihko P; Vihko R
Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution in normal mice of an 111In-labelled prostatic acid phosphatase-specific antibody and its F(ab')2 fragments derivatized site-specifically or via bicyclic diethylenetriaminepentaacetic acid anhydride.
Perälä M; Vihko P; Södervall M; Heikkilä J; Vihko R
Eur J Nucl Med; 1990; 16(8-10):621-6. PubMed ID: 2384100
[TBL] [Abstract][Full Text] [Related]
5. Radiation absorbed dose from indium-111-CYT-356.
Mardirossian G; Brill AB; Dwyer KM; Kahn D; Nelp W
J Nucl Med; 1996 Sep; 37(9):1583-8. PubMed ID: 8790224
[TBL] [Abstract][Full Text] [Related]
6. Dosimetric evaluation of immunoscintigraphy using indium-111-labeled monoclonal antibody fragments in patients with ovarian cancer.
Buijs WC; Massuger LF; Claessens RA; Kenemans P; Corstens FH
J Nucl Med; 1992 Jun; 33(6):1113-20. PubMed ID: 1597725
[TBL] [Abstract][Full Text] [Related]
7. Effects of tumour mass and circulating antigen on the biodistribution of 111In-labelled F(ab')2 fragments of human prostatic acid phosphatase monoclonal antibody in nude mice bearing PC-82 human prostatic tumour xenografts.
Perälä-Heape M; Vihko P; Laine A; Heikkilä J; Vihko R
Eur J Nucl Med; 1991; 18(5):339-45. PubMed ID: 1936042
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging.
Rijks LJ; Busemann Sokole E; Stabin MG; de Bruin K; Janssen AG; van Royen EA
Eur J Nucl Med; 1998 Jan; 25(1):40-7. PubMed ID: 9396873
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunodetection of prostate cancer by 111In-labeled monoclonal antibody against prostatic acid phosphatase.
Ahonen A; Kairemo K; Karnani P; Heikkilä J; Nurmi M; Teräs M; Lukkarinen O
Acta Oncol; 1993; 32(7-8):723-7. PubMed ID: 8305218
[TBL] [Abstract][Full Text] [Related]
11. In vivo behavior of 111In-labeled monoclonal anti-prostatic acid phosphatase antibody after intraprostatic and intravenous injections.
Kairemo KJ; Rannikko S; Nordling S; Savalainen S; Ahonen A; Taavitsainen MJ; Alfthan OS
J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):151-5. PubMed ID: 7632761
[TBL] [Abstract][Full Text] [Related]
12. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
[TBL] [Abstract][Full Text] [Related]
16. Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients.
Cremonesi M; Ferrari M; Chinol M; Stabin MG; Grana C; Prisco G; Robertson C; Tosi G; Paganelli G
Eur J Nucl Med; 1999 Feb; 26(2):110-20. PubMed ID: 9933344
[TBL] [Abstract][Full Text] [Related]
17. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Pandit-Taskar N; O'Donoghue JA; Ruan S; Lyashchenko SK; Carrasquillo JA; Heller G; Martinez DF; Cheal SM; Lewis JS; Fleisher M; Keppler JS; Reiter RE; Wu AM; Weber WA; Scher HI; Larson SM; Morris MJ
J Nucl Med; 2016 Dec; 57(12):1858-1864. PubMed ID: 27516450
[TBL] [Abstract][Full Text] [Related]
19. Effect of conjugation on the biodistribution of 111In-labelled anti-PAP and anti-PSA monoclonal antibodies examined in nude mice with PC-82 human tumor xenografts.
Perälä-Heape M; Vihko P; Pelkonen I; Laine A; Vihko R
In Vivo; 1991; 5(2):159-65. PubMed ID: 1722716
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and biodistribution in relation to tumour detection with 111In-labelled OV-TL 3 F(ab')2 in patients with ovarian cancer.
Massuger LF; Claessens RA; Kenemans P; Verheijen RH; Boerman OC; Meeuwis AP; Schijf CP; Buijs WC; Hanselaar TG; Corstens FH
Nucl Med Commun; 1991 Jul; 12(7):593-609. PubMed ID: 1923151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
